Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

January 31, 2010

Conditions

Chronic Myelogenous Leukemia

Interventions

DRUG

nilotinib

Trial Locations (3)

Novartis Investigative Site, Gdansk

Novartis Investigative Site, Poznan

Novartis Investigative Site, Warsaw